CVS Health Corp (CVS) concluded trading on Wednesday at a closing price of $66.6, with 10.81 million shares of worth about $720.17 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 49.70% during that period and on July 02, 2025 the price saw a loss of about -4.28%. Currently the company’s common shares owned by public are about 1.27B shares, out of which, 1.26B shares are available for trading.
Stock saw a price change of 0.35% in past 5 days and over the past one month there was a price change of 4.72%. Year-to-date (YTD), CVS shares are showing a performance of 12.77% which increased to 48.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $43.56 but also hit the highest price of $72.51 during that period. The average intraday trading volume for CVS Health Corp shares is 9.79 million. The stock is currently trading 0.25% above its 20-day simple moving average (SMA20), while that difference is up 2.30% for SMA50 and it goes to 10.18% higher than SMA200.
CVS Health Corp (NYSE: CVS) currently have 1.27B outstanding shares and institutions hold larger chunk of about 86.66% of that.
The stock has a current market capitalization of $84.25B and its 3Y-monthly beta is at 0.60. PE ratio of stock for trailing 12 months is 15.91, while it has posted earnings per share of $4.19 in the same period. Its PEG reads 1.15 and has Quick Ratio of 0.63 while making debt-to-equity ratio of 1.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CVS, volatility over the week remained 2.30% while standing at 2.05% over the month.
Stock’s fiscal year EPS is expected to rise by 13.02% while it is estimated to increase by 15.13% in next year. EPS is likely to grow at an annualized rate of 13.80% for next 5-years, compared to annual growth of -6.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering an Outperform rating for the stock and assigned a target price range of between $55 and $75 to it. On January 30, 2025, Edward Jones Upgrade their recommendations, while on December 03, 2024, Deutsche Bank Upgrade their ratings for the stock with a price target of $66. Stock get an Overweight rating from Wells Fargo on November 18, 2024.
